Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.58 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.57 |
| ▸ | AMY2A | P04746 | 4/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | IGF2R | P11717 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SELL | P14151 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211506 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL17211572 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL16312445 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL4117690 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL18025279 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL4118240 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL17211494 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL17448413 | 1.00 | CD209 (0.58) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL16190370 | 0.99 | CD209 (0.57) | CD209ENGASEAMY2ALGALS8LGALS3 | |
| SCHEMBL18333474 | 0.99 | CD209 (0.57) | CD209ENGASEAMY2ALGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306235-A1 | SUGAR CHAIN-ATTACHED LINKER, COMPOUND CONTAINING SUGAR CHAIN-ATTACHED LINKER AND PHYSIOLOGICALLY ACTIVE SUBSTANCE OR SALT THEREOF, AND METHOD FOR PRODUCING SAME | GLYTECH INC (JP) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306235-A1 | SUGAR CHAIN-ATTACHED LINKER, COMPOUND CONTAINING SUGAR CHAIN-ATTACHED LINKER AND PHYSIOLOGICALLY ACTIVE SUBSTANCE OR SALT THEREOF, AND METHOD FOR PRODUCING SAME | SI, ENGASE, DNPEP | CD209 709/4885ENGASE 2/4885AMY2A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.